🇺🇸 FDA
Pipeline program

VORICONAZOLE, ANIDULAFUNGIN, CASPOFUNGIN, AMPHOTERICINE B, LIPOSOME, FLUCONAZOLE, FLUCONAZOLE, AMPHOTERICINE B, LIPOSOME, VORICONAZOLE, ANIDULAFUNGIN, CASPOFUNGIN, MICAFUNGIN, MICAFUNGIN

APHP230824

Phase 3 small_molecule active

Quick answer

VORICONAZOLE, ANIDULAFUNGIN, CASPOFUNGIN, AMPHOTERICINE B, LIPOSOME, FLUCONAZOLE, FLUCONAZOLE, AMPHOTERICINE B, LIPOSOME, VORICONAZOLE, ANIDULAFUNGIN, CASPOFUNGIN, MICAFUNGIN, MICAFUNGIN for Uncomplicated candidemia is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Uncomplicated candidemia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials